Index by author
Antonelli, Maria J.
- The constellation of vitamin D, the acute-phase response, and inflammation
An astronomic increase in vitamin D testing and supplementation is happening in the absence of an evidence-based rationale.
Calle, Juan
Resistant hypertension: A stepwise approachThe authors review the definition and prevalence of resistant hypertension and its diagnostic workup and management, including lifestyle modifications, drugs, and experimental therapies.
Epstein, Murray
- The constellation of vitamin D, the acute-phase response, and inflammation
An astronomic increase in vitamin D testing and supplementation is happening in the absence of an evidence-based rationale.
Hayashi, Kamichika
- Oral leukoplakia and oral cancer
A 53-year-old male who had smoked for 36 years was referred by his dentist for worsening vitiligo diagnosed as leukoplakia 3 years earlier.
Katakura, Akira
- Oral leukoplakia and oral cancer
A 53-year-old male who had smoked for 36 years was referred by his dentist for worsening vitiligo diagnosed as leukoplakia 3 years earlier.
Kushner, Irving
- The constellation of vitamin D, the acute-phase response, and inflammation
An astronomic increase in vitamin D testing and supplementation is happening in the absence of an evidence-based rationale.
Li, Yuebing
- Myasthenia gravis: Frequently asked questions
Who is at risk? Which tests should be ordered? How does the disease course affect management decisions? What instructions should you give patients? And other questions.
Long, Bruce
- Vitamin D: A metabolic bone disease perspective
When checking levels, clinicians should keep in mind that vitamin D levels fluctuate by season and time of day, and that different laboratories may use different assays that yield different results.
Mandell, Brian F.
- Myasthenia gravis: An update for internists
Recognizing the spectrum of the disease in patients’ complaints enhances our clinical reasoning skills when faced with the extremely commonly expressed symptom of “fatigue.”
Morren, John A.
- What are the treatment options for myasthenia gravis if first-line agents fail?
From 5% to 20% of patients may have a suboptimal response or prohibitive adverse effects over a period of a few weeks to 3 months.
- Myasthenia gravis: Frequently asked questions
Who is at risk? Which tests should be ordered? How does the disease course affect management decisions? What instructions should you give patients? And other questions.
